Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03174275 · OUTCOME

Pathologic Complete Response Rate (pCRR) After Induction Chemotherapy With Carboplatin, Nab-paclitaxel, and Durvalumab in Previously Untreated Stage III and IV SCCHN Amenable to Surgical Resection

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma · Source last updated 2026-02-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
After surgery (approximately 8-12 weeks after start of study treatment)

What was measured

The pCRR was assessed via surgical pathology report. Pathologic complete response will require no viable cancer cells on the surgical pathology report after neoadjuvant treatment with carboplatin, nab-paclitaxel, and durvalumab. This study protocol requires the same neoadjuvant therapy and surgery for all subjects. The primary outcome measure is the complete pathologic response defined by the surgical pathology report and is unrelated to adjuvant therapy.

Analysis population: Subjects received treatment in 4 cancer centers in the United States.

Groups in this outcome

Pathologic Complete Response

All subjects received neoadjuvant chemotherapy and underwent surgery, and histopathological analyses were completed.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pathologic Complete Response35

Reported measurements

Pathologic complete response was achieved
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pathologic Complete Response10Not reportedNot reportedNot reportedNot reported
Pathologic complete response was not achieved
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pathologic Complete Response25Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        10
    title
    Pathologic complete response was achieved
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        25
    title
    Pathologic complete response was not achieved
denoms
  1. counts
    1. group Id
      OG000
      value
      35
    units
    Participants
description
The pCRR was assessed via surgical pathology report. Pathologic complete response will require no viable cancer cells on the surgical pathology report after neoadjuvant treatment with carboplatin, nab-paclitaxel, and durvalumab. This study protocol requires the same neoadjuvant therapy and surgery for all subjects. The primary outcome measure is the complete pathologic response defined by the surgical pathology report and is unrelated to adjuvant therapy.
groups
  1. description
    All subjects received neoadjuvant chemotherapy and underwent surgery, and histopathological analyses were completed.
    id
    OG000
    title
    Pathologic Complete Response
param Type
COUNT_OF_PARTICIPANTS
population Description
Subjects received treatment in 4 cancer centers in the United States.
reporting Status
POSTED
time Frame
After surgery (approximately 8-12 weeks after start of study treatment)
title
Pathologic Complete Response Rate (pCRR) After Induction Chemotherapy With Carboplatin, Nab-paclitaxel, and Durvalumab in Previously Untreated Stage III and IV SCCHN Amenable to Surgical Resection
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice